Chemical exchange saturation transfer (CEST) with multiparametric quantitative magnetic resonance imaging (qMRI) is a potential prognostic biomarker for patients with glioblastoma multiforme (GBM) undergoing chemoradiation (CRT).
Why this matters
GBM is the most common and aggressive primary malignant brain tumor, with poor overall progression-free survival rates. Identification of patients with GM who will progress early remains a challenge with clinical implications for treatment adaptation.
CEST is a novel image contrast for use with qMRI, and CEST at 3T and 7T have been suggested to predict response to therapy. However, the use of CEST at 1.5T would enable a broader use in MR-guided radiotherapy.
The results of this study indicate that the use of CEST at 1.5T is able to distinguish between tumor and contralateral normal-appearing white matter (cNAWM) as well as predict early progression, and warrants further investigation.